A long-term followup study on Boston Scientific’s (NYSE:BSX) Watchman heart implant shows low risk of hemorrhagic stroke and a high percentage of patients who discontinued anticoagulation drugs at one year. Published this week in the Journal of the American College of Cardiology, the new registry data represent the largest number and longest follow-up of patients […]
This article has been updated to include comments from Boston Scientific. A recent review of FDA files has found nearly 3,000 adverse events related to Boston Scientific’s (NYSE:BSX) Watchman device. The Watchman left atrial appendage closure device, approved by the agency in March 2015, is designed to prevent blood clots that form in the heart’s […]
Drug-coated balloon treatments reduce the risk of target lesion revascularization in treating femoropopliteal artery disease by 67% when compared to plain balloon angioplasty procedures, according to a new study. Results from the study were published in the Journal of the American College of Cardiology: Cardiovascular Interventions. The study aimed to compared the risk of target […]
A small, early feasibility study showed good results in high-risk patients treated with the Fortis mitral valve replacement made by Edwards Lifesciences (NYSE:EW). Data from the 3-patient study, published this month in the Journal of the American College of Cardiology, showed successful implantation of the Fortis transcatheter mitral valve implant with no major complications. Echocardiograms at discharge […]
Treatment with another stent, rather than from a drug-coated or drug-eluting balloon, has been shown to be more effective in treating coronary in-stent restenosis, according to 2 new studies. The 2 studies, 1 European and 1 Japanese, were published in the Journal of the American College of Cardiology earlier this month. The 309-patient European Ribs […]
A pivotal clinical trial of Tryton Medical‘s side-branch stent, the largest ever conducted on coronary bifurcation lesions, failed to meet its primary endpoint for target vessel failure.
Infraredx touted a study in the Journal of the American College of Cardiology showing its imaging technology could help cardiologists assess a patient’s risk for suffering a heart attack or stroke.
Louis Krami, CEO of Idaho’s Bingham Memorial Hospital, admitted to 2nd degree stalking charges after he ordered hospital IT staff to record the phone calls of former Bingham doctor Robert Rosin and his staff.
In the culmination of the 18-month investigation, Krami faces 30 days in behind bars, a $1,000 fine and 100 hours of community service. Hospital IT employees Chris Behunin, Tyler Lassen and IT director Jack York were also implicated in the illegal wiretap activity.